CEPI Competitors, Revenue, Alternatives and Pricing

Claim your profile


Oslo, NOR Norway
Total Funding:N/A
Lead Investor(s):N/A

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • CEPI's estimated annual revenue is currently $13.2M per year.(?)
  • CEPI's estimated revenue per employee is $102,000

Employee Data

  • CEPI has 129 Employees.(?)
  • CEPI grew their employee count by 34% last year.
  • CEPI currently has 1 job openings.

CEPI - Coalition for Epidemic Preaparedness Innovations - is a new broad international coalition set up to fund development of vaccines against emerging infectious diseases with epidemic potential, where there are few market incentives. The epidemics like Ebola and SARS we have seen over the past years, have demonstrated the need for vaccines. Development of a vaccine takes many years, and it is too late to start when the outbreak has started. By having vaccines on the shelf ready for phase III early in an outbreak, we can demonstrate the vaccine efficacy and stop the outbreak while it is small. CEPI has already launched two calls for proposals; one for development of vaccines against MERS, Lassa and Nipah and one for the development of rapid response vaccine technology to enable development of vaccines against new and unknown diseases. CEPI was launched in January 2017 and now has funding totalling $620 million from soverign investors and philantropic institutions. CEPI's investors are: The Governments of Australia, Belgium, Canada, Japan and Norway, as well as the Wellcome Trust and the Bill&Melinda Gates Foundation. In addition the European Commission will co fund activities with 250 million.